Technical Analysis for JAZZ - Jazz Pharmaceuticals plc

Grade Last Price % Change Price Change
grade F 110.06 0.41% 0.45
JAZZ closed down 0.66 percent on Wednesday, July 1, 2020, on 73 percent of normal volume. It ran into resistance at its 50 day moving average.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Down
Historical JAZZ trend table...

Date Alert Name Type % Chg
20 DMA Resistance Bearish 0.41%
50 DMA Resistance Bearish 0.41%
180 Bearish Setup Bearish Swing Setup 0.41%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.41%
Multiple of Ten Bearish Other 0.41%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -0.25%
Multiple of Ten Bullish Other -0.25%
Outside Day Range Expansion -0.25%
Inside Day Range Contraction 1.96%
Multiple of Ten Bullish Other -0.03%

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Jazz Pharmaceuticals Public Limited Company, a specialty biopharmaceutical company, engages in the identification, development, and commercialization of pharmaceutical products for various medical needs in the United States, Europe, and other countries. The company's products include Xyrem for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy; Erwinaze to treat acute lymphoblastic leukemia; Prialt for the management of severe chronic pain; and FazaClo LD and FazaClo HD, which are orally disintegrating clozapine tablets for the resistant schizophrenia treatment. It also provides Luvox CR to treat obsessive compulsive disorder; Versacloz oral suspension; Caphosol to treat oral mucositis; Quadramet for the treatment of pain in patients whose cancer has spread to the bones; ProstaScint for imaging the extent and spread of prostate cancer; Niravam for the treatment of generalized anxiety and panic disorders; and Parcopa for the symptoms associated with idiopathic Parkinson's disease treatment. In addition, the company offers Collatamp, a surgical implant impregnated with the antibiotic gentamicin; Fomepizole to treat ethylene glycol poisoning; Kidrolase for treating ALL, Leukaemic meningitis, and non-Hodgkin's lymphoma; Xenazine to treat movement disorders associated with Huntington's chorea and hemiballismus; and Custodiol, a ready to use solution used in organ transplantation. Further, it develops Asparec, a pegylated recombinant Erwinia asparaginase that is in Phase I clinical trials for the treatment of patients with ALL with E. coli asparaginase hypersensitivity; and Leukotac, an anti-CD25 monoclonal antibody is in Phase III clinical trials for the treatment of steroid-refractory acute graft vs. host diseases. The company markets its products through its sales representatives, distributors, and wholesalers, as well as through third party vendors. Jazz Pharmaceuticals Public Limited Company is headquartered in Dublin, Ireland.
Medicine Biotechnology Biopharmaceutical Cancer Clinical Medicine Pain Drugs Imaging Pharmaceutical Products Prostate Cancer Lymphoma Pharmacokinetics Transplantation Movement Disorders Acute Lymphoblastic Leukemia Obsessive Compulsive Disorder Pegylation Severe Chronic Pain Host Diseases Mucositis Narcolepsy Oral Hygiene Asparaginase Cataplexy

Is JAZZ a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 154.24
52 Week Low 86.9539
Average Volume 695,255
200-Day Moving Average 125.51
50-Day Moving Average 111.90
20-Day Moving Average 111.55
10-Day Moving Average 110.83
Average True Range 4.00
ADX 16.2
+DI 19.46
-DI 25.27
Chandelier Exit (Long, 3 ATRs ) 112.99
Chandelier Exit (Short, 3 ATRs ) 113.82
Upper Bollinger Band 119.56
Lower Bollinger Band 103.55
Percent B (%b) 0.38
BandWidth 14.36
MACD Line -0.83
MACD Signal Line -0.55
MACD Histogram -0.2813
Fundamentals Value
Market Cap 6.59 Billion
Num Shares 60.1 Million
EPS 6.49
Price-to-Earnings (P/E) Ratio 16.89
Price-to-Sales 5.40
Price-to-Book 3.78
PEG Ratio 0.72
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 113.29
Resistance 3 (R3) 113.69 112.86 112.67
Resistance 2 (R2) 112.86 111.93 112.66 112.47
Resistance 1 (R1) 111.24 111.35 110.83 110.84 112.26
Pivot Point 110.41 110.41 110.21 110.21 110.41
Support 1 (S1) 108.79 109.48 108.38 108.39 106.96
Support 2 (S2) 107.96 108.90 107.76 106.75
Support 3 (S3) 106.34 107.96 106.55
Support 4 (S4) 105.94